Psychotherapy for depression: No stronger medicine.

Comments on the work by R. F. Mu?oz et al (see record 1994-31016-001), commending them for their review and evaluation of the Agency for Health Care Policy and Research (1993) Depression in Primary Care guidelines. However, the recommendation to combine psychotherapy and pharmacotherapy is criticized. (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Corporate funding and conflicts of interest: A primer for psychologists.

A presidential task force on external funding was established by the American Psychological Association (APA) in 2003 to review APA policies, procedures, and practices regarding the acceptance of funding and support from private corporations for educational and training programs; continuing education offerings; research projects; publications; advertising; scientific and professional meetings and conferences; and consulting, practice, and advocacy relationships. This article, based on the Executive Summary of the APA Task Force on External Funding Final Report, presents the findings and unanimous recommendations of the task force in the areas of association income, annual convention, research and journals, continuing education, education, practice, and conflicts of interest and ethics. The task force concluded that it is important for both APA and individual psychologists to become familiar with the challenges that corporate funding can pose to their integrity. The nature and extent of those challenges led the task force to recommend that APA develop explicit policies, educational materials, and continuing education programs to preserve the independence of psychological science, practice, and education. (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Psychotherapy versus medication for depression: Challenging the conventional wisdom with data.

Antidepressant medications are the most popular treatment for unipolar depression in the US, although there may be safer alternatives that are equally or more effective. This article reviews a wide range of well-controlled studies comparing psychological and pharmacological treatments for depression. The evidence suggests that the psychological interventions, particularly cognitive behavioral therapy, are at least as effective as medication in the treatment of depression, even if severe. These conclusions hold for both vegetative and social adjustment symptoms, especially when patient-rated measures are used and long-term follow-up is considered. Some aspirational guidelines for the treatment of depression are proposed. (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Prediction of individual outcome in a group intervention for depression.

75 Ss (mean age 36 yrs) who met Research Diagnostic Criteria for a current episode of Major, Minor, or Intermittent Depressive Disorder were assessed on a number of demographic and psychological variables prior to beginning treatment. Treatment outcome was assessed by the Beck Depression Inventory and the Schedule for Affective Disorders and Schizophrenia. Ss at all levels of depression severity improved markedly, but those who were initially more depressed tended to maintain their relative ranking at posttreatment. After accounting for pretreatment depression severity (PTDS), 6 additional variables emerged as significant predictors of outcome: Ss who improved most had expected to be least depressed posttreatment, had greater perceptions of mastery, had greater reading ability, were younger, perceived their families as more supportive, and were not receiving additional concurrent treatment for depression. These 7 variables, including PTDS, accounted for 51% of the variance in posttreatment depression level. These same variables, excluding PTDS, significantly discriminated between Ss who still met diagnostic criteria for depression at the posttreatment assessment and those who were no longer depressed. (29 ref) (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Identification of therapist differences in a group treatment for depression.

Examined therapist variables presumed to be related to outcome in a structured, cognitive-behavioral group treatment for depression. Each of 8 leaders conducted 2 consecutive psychoeducational treatment groups consisting of 5–8 Ss. Of the 106 Ss (aged 17–67 yrs) who participated in the study, 79 were clinically depressed; measures of depression included the Beck Depression Inventory, Hamilton Rating Scale for Depression, and a measure of social adjustment. A broad multivariate assessment was conducted of pretreatment leader characteristics, leader behavior and style during treatment, group behavior and process, and depression outcome. Results indicate that leaders differed significantly on behavioral and group-process measures, but differences in depression outcome between leaders did not attain statistical significance. (5 ref) (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Transdermal nicotine: The long and the short of it.

Cigarette smokers with a mean history of 35 smoking years (N?=?98) were randomly assigned to receive either 3 weeks or 12 weeks of transdermal nicotine treatment combined with a 5-session behavioral management program. Participants were followed for 20 weeks. At the conclusion of the study, 26% of the 3-week participants and 29% of the 12-week participants were abstinent. The number of abstinent participants and duration of abstinence were not significantly different between the 2 groups, although statistical power constraints do not rule out the possibility of small undetected differences in outcome. Most participants (68%) smoked at least once during their nicotine patch regimen. Smoking on the patch was associated with poor outcome. Those who smoked while using the patch reported more restlessness and cigarette cravings and lower confidence and intention to quit smoking than did participants who did not smoke during the drug regimen. (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Astrocomp: web technologies for high performance computing on a network of supercomputers

Astrocomp is a project developed by the INAF-Astrophysical Observatory of Catania, University of Roma La Sapienza and Enea in collaboration with Oneiros s.r.l. The project has the goal of building a web-based user-friendly interface which allows the international community to run some parallel codes on a set of high-performance computing (HPC) resources, with no need for specific knowledge about Unix and Operating Systems commands. Astrocomp provides CPU times, on parallel systems, available to the authorized user. The portal makes codes for astronomy available: FLY code, a cosmological code for studying three-dimensional collisionless self-gravitating systems with periodic boundary conditions [Becciani, Antonuccio, Comput. Phys. Comm. 136 (2001) 54]. ATD treecode, a parallel tree-code for the simulation of the dynamics of self-gravitating systems [Miocchi, Capuzzo Dolcetta, A&A 382 (2002) 758]. MARA a code for stellar light curves analysis [Rodonò et al., A&A 371 (2001) 174]. Other codes will be added to the portal in the future.     

Raising questions about antidepressants

Antidepressant medication has apparently become the most popular treatment for depression in the USA. Several beliefs about the efficacy of antidepressant medications prevail among mental health professionals and the public. This paper explores relevant research data and raises questions about these beliefs. Many of the common beliefs about these medications are not adequately supported by scientific data. The following issues are raised: (1) industry-funded research studies which result in negative findings sometimes do not get published; (2) placebo washout procedures may bias results in some studies; (3) there are serious questions about the integrity of the double-blind procedure; (4) the 'true' antidepressant drug effect in adults appears to be relatively small; (5) there is minimal evidence of antidepressant efficacy in children; (6) side effects are fairly common even with the newer antidepressants; (7) combining medications raises the risk for more serious complications; (8) all antidepressants can cause withdrawal symptoms; (9) genetic influences on unipolar depression appear to be weaker than environmental influences; (10) biochemical theories of depression are as yet unproven; (11) biological markers specific for depression have been elusive; (12) dosage and plasma levels of antidepressants have been minimally related to treatment outcome; (13) preliminary evidence suggests that patients who improve with cognitive-behavioral psychotherapy show similar biological changes as those who respond to medication, and (14) the evidence suggests that psychological interventions are at least as effective as pharmacotherapy in treating depression, even if severe, especially when patient-rated measures are used and long-term follow-up is considered.